Bayer 12006 : Essai de phase 3 randomisé, en double aveugle, évaluant l’efficacité de 2 associations thérapeutiques comprenant la gemcitabine, le cisplatine et soit le sorafenib, soit un placebo, chez des patients ayant un cancer du poumon non à petites cellules de stade IIIb avec effusion ou de stade IV. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer l’efficacité d’un traitement associant le sorafenib à la gemcitabine et au cisplatine dans le traitement des patients ayant un cancer du poumon non à petites cell...

• Country France
• organs Poumon, type non à petites cellules
• Specialty Thérapies Ciblées, Chimiothérapie

A randomized, explorative, double-blind, double-dummy, multi-center, parallel group study to assess sustainable efficacy of once daily vardenafil (10 mg) for 12 and 24 weeks versus vardenafil PRN in men with mild or mild to moderate erectile dysfunction The objective of this study is to explore the prophylactic (prophylaxis of deterioration) or curative efficacy and safety of long-term (12 and 24 weeks) daily administration of vardenafil therapy (adm...

• Country None
• organs None
• Specialty None

To assess safety and tolerability, clinical effects of riociguat. To provide access to riociguat for patients with in-operable chronic thromboembolic pulmonary hypertension (CTEPH), or recurrent or persisting pulmonary hypertension (PH) after surgical treatment who are not satisfactorily treated and cannot participate in any other CTEPH trial •To assess safety and tolerability, clinical effects of riociguat.. •To provide access to riociguat for patients with in-operable chronic thromboembolic pulmonary hypertension (CTEPH), or recurrent o...

• Country None
• organs None
• Specialty None

Study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY 63-2521 after dosing of a 2 mg tablet in 20 patients with Raynaud’s phenomenon (RP) The primary objective of the study is to investigate the safety, tolerability and pharmacodynamics of a single oral dose of BAY 63-2521 administered in patients suffering from Raynaud’s phenomenon

• Country None
• organs None
• Specialty None

Bayer-15977 : Essai de phase 1 visant à évaluer l’efficacité et la tolérance du sorafénib en association avec l’éribuline, chez des patients ayant une tumeur solide avancée, métastatique ou réfractaire. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] L’objectif de cet essai est d’évaluer la tolérance et l’efficacité du sorafénib en association avec l’éribuline, chez des patients ayant une tumeur solide avancée, métastatique ou réfractaire. Les pa...

• Country France
• organs Tumeurs solides, Sein
• Specialty Thérapies Ciblées, Chimiothérapie

The ARRIVE Study (Aspirin to Reduce Risk of Initial Vascular Events) - A Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel Group Study to Assess the Efficacy (Reduction of Cardiovascular Disease Events) and Safety of 100 mg Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease To evaluate the clinical effect of a 100 mg/day enteric coated aspirin vs placebo in the reduction of CVD events in patients at moderate risk of CHD events (approx 10 - 20% 10 year-risk). This corresp...

• Country None
• organs None
• Specialty None

Monocenter, open-label, randomized study to determine the ovulation inhibitory effect of the combined oral contraceptives SH T04769G (0.015 mg Ethinylestradiol and 1.5 mg Dienogest in a modified release medicinal product) and SH D00659AF (0.03 mg Ethinylestradiol and 2.0 mg Dienogest), applied for two treatment cycles to 60 healthy female volunteers The aim of the study is to determine the ovulation inhibitory effect of the COC SH T04769G (0.015 mg Ethinylestradiol and 1.5 mg Dienogest in a modified release film-coated tablet) and to collect sup...

• Country None
• organs None
• Specialty None

Randomized, double-blind, placebo-controlled, parallel group study of vardenafil 10 mg twice daily to assess the effect on urodynamics in patients with Overactive Bladder (detrusor overactivity) To determine the therapeutic effect of vardenafil on Overactive Bladder by means of urodynamic measurements (filling cystometry and pressure flow investigations). In addition, a micturition diary wil...

• Country None
• organs None
• Specialty None

Refametinib given to patients with unresectable or metastatic HCC carrying a RAS mutation The primary objective is to evaluate the efficacy of refametinib in patients with KRAS or NRAS mutant unresectable or metastatic HCC.

• Country None
• organs None
• Specialty None

Early Diabetes Intervention Trial Not provided at time of registration

• Country None
• organs None
• Specialty None